Magellan Rx Report

Our award-winning report provides insights on the industry’s most innovative and groundbreaking managed care solutions for some of the most complex areas of healthcare.

Download our 2019 Media Kit today!

NTRK Spotlight
NTRK Gene Fusions: Tumor-Agnostic Cancer Therapies and the Importance of Testing
  • NTRK Gene Fusions
  • Incidence of NTRK Gene Fusions
  • Inhibitors and Pipeline
  • Gene Fusion Testing
  • NGS Testing: DNA-Based and RNA-Based
Summer 2019
  • Strategies for Staying Ahead of Specialty Drug Trends
  • Medical Oncology Biosimilars
  • Psoriasis Update
  • Leveraging Technology to Improve Medication Adherence and Optimize Health Outcomes
  • Pipeline Drug List
Spring 2019
  • Migraine Management
  • Trends in Oncology Management
  • Digital Therapeutics
  • Rare Disease Management
  • Pharmacogenetics in Managed Care
Fall 2018
  • Multiple Sclerosis
  • PI3K Inhibitors Pipeline
  • Multiple Myeloma Treatment
  • PARP Inhibitors in Ovarian Cancer
  • Opioid Use Disorder
Summer 2018
  • Biosimilars
  • High-Cost Therapy Payment Strategies
  • Cystic Fibrosis
  • Asthma
  • Human Immunodeficiency Virus
Spring 2018
  • Orphan Diseases
  • Alzheimer’s Disease
  • The Opioid Crisis
  • Migraine Pipeline & Treatment
Fall 2017
  • CAR-T and Gene Therapies
  • Opioid-Induced Constipation
  • Osteoporosis in the Managed Care Setting
  • Star Ratings and Quality Improvement
  • Variable Fee Schedule Reimbursement
Summer 2017
  • Migraine Treatment
  • PD-1 and PD-L1 Inhibitors
  • Computerized Cognitive Behavioral Therapy
  • Hemophilia
Spring 2017
  • Personalizing Medicine to Transition Oncology Care
  • Type 2 Diabetes
  • Inflammatory Conditions
  • Immune Globulin
Fall 2016
  • Asthma Management
  • HIV
  • PAH
  • Melanoma
  • LARCs
Summer 2016
  • Biosimilars
  • Multiple Myeloma
  • Medical Drug Management Strategies
  • Long-Acting Injectable Antipsychotics
  • Value Based PBM
Spring 2016
  • PCSK9 Inhibitors and Hypercholesterolemia
  • Real-World Studies
  • AMD
  • Medical Pharmacy Expenditures
  • PD-1 Inhibitors
Fall 2015
  • Pulmonary Arterial Hypertension and Pulmonary Fibrosis
  • Treating Opioid Dependency
  • ACOs
  • Evaluating AMD
  • Improving Star Ratings
Summer 2015
  • Hemophilia
  • PCMH Model
  • Site of Care
  • Medical Pharmacy Solutions
  • Medicare Part D Regulations
Spring 2015
  • PCSK9 Inhibitors
  • Next Generation Sequencing
  • Hepatitis C
  • Opioid Dependency
  • Multiple Sclerosis
Fall 2014
  • Hepatitis C Virus
  • Optimizing HAE
  • CLL Treatment
  • Metastatic Melanoma
  • Infliximab Site of Care
Summer 2014
  • Heart Failure Management
  • Immune Globulin Therapy
  • Star Ratings
  • Quality Improvement in Diabetes
Spring 2014
  • Specialty Management Solutions
  • Prostate Cancer
  • Biosimilars
  • Immune Globulin
  • Renal Cell Carcinoma
Fall 2013
  • A New Era of Oncology Management
  • CML
  • Oral Oncology
  • Understanding Hemophilia
Summer 2013
  • New Generation of Specialty Management
  • Gaucher Disease
  • Managing Hereditary Angiodema
  • Neurotoxins
  • Antiplatelet Therapy for ACS
Spring 2013
  • Specialty Management
  • Immune Globulin Therapy
  • Reproductive Therapies
  • Prostate Cancer
  • Adherence in Patients with HIV
Fall 2012
  • Specialty Management Solutions
  • Innovations in Prostate Cancer Treatment
  • Inside a Pioneer ACO
  • Future Impact of Biosimilars
  • Specialty Trends Update
Summer 2012
  • CMS Star Ratings
  • Transitioning to the Pioneer ACO Model
  • Benefits of Motivational Interviewing
  • The PPACA Contraception Mandate
  • Pediatric Buprenorphine Exposure
Spring 2012
  • Managed Care Solutions
  • Cost-Effectiveness of Oral Anticoagulants
  • CMS Stars
  • New MLR Requirements
  • Transitioning to Accountable Care
Fall 2011
  • Managed Care Solutions
  • GLP-1 Agonists
  • CMS Star Ratings
  • The Clinical Benefits of Prior Authorizations
  • Navigating Accountable Care Organizations
Spring 2011
  • Diabetes Management
  • Asthma Controller Medication
  • Type 2 Diabetes
  • Improving Your Star Ratings
  • Effects of Medication Reconciliation on Readmissions